Changes in Helicobacter pylori-induced gastritis in the antrum and corpus during 12 months of treatment with omeprazole and lansoprazole in patients with gastro-oesophageal reflux disease

Alimentary Pharmacology and Therapeutics

Volumn 12, Issue 3, 1998, Pages 247-253

  Stolte, M ^a   Meining, A ^a   Schmitz, J M ^a   Alexandridis, T ^b   Seifert, E ^c  

^a INSTITUTE OF PATHOLOGY   (Germany)

^b Takeda Pharma GmbH   (Germany)

^c Stadtisches Krankenhaus Kemperhof   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE; OMEPRAZOLE;

ARTICLE; BIOPSY; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; ENDOSCOPY; ERADICATION THERAPY; GASTRITIS; GASTROESOPHAGEAL REFLUX; HELICOBACTER PYLORI; HISTOLOGY; HISTOPATHOLOGY; HUMAN; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH; STOMACH ANTRUM; STOMACH MUCOSA;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-ULCER AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GASTRITIS; GASTROESOPHAGEAL REFLUX; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; OMEPRAZOLE; PYLORIC ANTRUM; SEVERITY OF ILLNESS INDEX; STOMACH; TIME FACTORS;

EID: 0031898529     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1998.00310.x     Document Type: Article

References (26)

1. Roland M, Berstad A, Liavåg I. A histological study of gastric mucosa before and after proximal gastric vagotomy in duodenal ulcer patients. Scan J Gastroenterol 1975; 10: 181-6.
2. Jönsson KÄ, Ström M, Bodemar G, Norrby K. Histological changes in the gastroduodenal mucosa after long-term medical treatment with cimetidine or parietal cell vagotomy in patients with juxtapyloric ulcer disease. Scand J Gastroenterol 1988; 23: 433-41.
3. Klinkenberg-Knol EC, Festen HPM, Jansen JBMJ, et al. Long-term treatment with omeprazole for refractory reflux esophagitis: efficacy and safety. Ann Intern Med 1994; 121: 161-7.
4. Lamberts R, Creutzfeldt W, Strüber HG, Brunner G, Solcia E. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology 1993; 104: 1356-70.
5. Kuipers EJ, Lundell L, Klinkenberg-Knol EC, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or funduplication. N Engl J Med 1996; 304: 1018-22.
6. Geboes K, Ectors N, Penson J, Leuven KU. Long-term lansoprazole treatment in man: effects on gastric mucosa histology. Gastroenterology 1995; 108: A99.
7. Baldi F, Bardhan KD, Bormann PC, et al. Lansoprazole maintains healing in patients with reflux esophagitis. Gastroenterology 1996; 254: A42.
8. Price AB. The Sydney system: histological division. J Gastroenterol Hepatol 1991; 6: 209-22.
9. Stolte M, Stadelmann O, Bethke B, Burkhard G. Relationship between the degree of Helicobacter pylori colonization and the degree and activity of gastritis, surface epithelial degeneration and mucus secretion. Z Gastroenterol 1995; 33: 89-93.
10. Solcia E, Villani L, Fiocca R, et al. Effect of eradication of Helicobacter pylori on gastritis in duodenal ulcer patients. Scand J Gastroenterol 1994; 29(Suppl. 201): 28-34.
11. Logan RPH, Walker MM, Misiewics JJ, et al. Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut 1995; 36: 12-16.
12. Stolte M, Bethke B. Elimination of Helicobacter pylori under treatment with omeprazole. Z Gastroenterol 1990; 28: 271-4.
13. Graham DY, Genta R, Evans DG, et al. Helicobacter pylori does not migrate from the antrum to the corpus in response to omeprazole. Am J Gastroenterol 1996; 91: 2120-34.
14. 2-receptor-antagonists as well as antacids have an aggravating effect on Helicobacter pylori gastritis in duodenal ulcer patients. Aliment Pharmacol Ther 1997; 11: 729-34.
15. Stolte M, Baumann H, Bethke B, Lauer E, Ritter M. Active autoimmune gastritis without total atrophy of the glands. Z Gastroenterol 1992; 30: 729-33.
16. Faller G, Steininger H, Eck M, et al. Antigastric autoantibodies in Helicobacter pylori gastritis: prevalence, in-situ binding sites and clues for clinical relevance. Virchows Arch 1996, 427(5): 483-6.
17. Negrini R, Savio A, Poiesi C, et al. Antigenic mimicry between Helicobacter pylori and gastric mucosa in the pathogenesis of body atrophic gastritis. Gastroenterology 1996; 111: 655-65.
18. Stolte M, Bethke B, Blum AL, Sulser E, Stadelmann O. Antacid treatment has a deleterious effect on the severity and activity of gastritis of the corpus mucosa. Ir J Med Sci 1992; 161 (Suppl 10): 6(Abstract).
19. Möller H, Nissen A, Mosbech J. Use of cimetidine and other peptic ulcer drugs in Denmark 1977-1990 with analysis of the risk of gastric cancer among cimetidine users. Gut 1992; 33: 1166-9.
20. La Vecchia C, Negri E, D'Avanzo B, Franceschi S. Histamine-2-receptor antagonists and gastric cancer risk. Lancet 1990; 336: 355-7.
21. Caygill CPJ, Knowles RL, Hall R. Increased risk of cancer mortality after vagotomy for peptic ulcer: a preliminary analysis. Eur J Cancer Prev 1991; 1: 35-7.
22. Lundegård G, Ekbom A, McLaughlin JK, Nyren O. Gastric cancer risk after vagotomy. Gut 1994; 35: 946-9.
23. Meining A, Bayerdörffer E, Hatz R, et al. Different expression of Helicobacter pylori gastritis in gastric cancer patients. Gut 1995; 37(Suppl. 1): 154A.
24. Eissele R, Brunner G, Simon B, Solcia E, Arnold R. Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterology 1997, 112: 707-17.
25. Meining A, Stolte M, Müller P, et al. Gastric carcinoma risk index in patients infected with Helicobacter pylori. Gastroenterology 1996; 110: A556.
26. Meining A, Stolte M. Different expression of H. pylori-gastritis in relatives of gastric carcinoma patients. Gut 1996; 39 (Suppl. 2): A17-18.